

Award Number: W81XWH-06-1-0252

TITLE: A Genetic Screen for Genes Involved in BRCA 1 Tumor Suppressor Function

PRINCIPAL INVESTIGATOR: Inder Verma
Quan Zhu

CONTRACTING ORGANIZATION: The Salk Institute for Biological Studies
La Jolla, CA 92037-1099

REPORT DATE: March 2007

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE 01-03-2007		2. REPORT TYPE Annual		3. DATES COVERED 1 Mar 2006 – 28 Feb 2007	
4. TITLE AND SUBTITLE A Genetic Screen for Genes Involved in BRCA 1 Tumor Suppressor Function				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-06-1-0252	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Inder Verma Quan Zhu Email: verma@salk.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The Salk Institute for Biological Studies La Jolla, CA 92037-1099				8. PERFORMING ORGANIZATION REPORT NUMBER	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES Original contains colored plates: ALL DTIC reproductions will be in black and white.					
14. ABSTRACT Based on our initial screening, we have identified a number of candidates that are involved in DNA damage repair pathway mediated by BRCA1, which is an important aspect of tumor suppression of the molecular. As none of the candidates have previously been reported to play a role in DNA damage repair pathway we speculate that some novel components, such as RNA or chromatin structure, might be involved. Once verified and fully investigated, the possible target genes will contribute to the understanding of the biology of inherited breast cancer as well as the diagnosis and treatment of breast, ovarian and possibly other cancers.					
15. SUBJECT TERMS candidates cooperating with BRCA1 to confer resistance to DNA damage					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	7	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	3
Body.....	3
Key Research Accomplishments.....	5
Reportable Outcomes.....	6
Conclusion.....	6
References.....	6
Appendices.....	n/a

INTRODUCTION

BRCA1, as well as BRCA2, were identified as the hereditary breast and ovarian cancer susceptibility genes that can account for almost all the entirety of inherited cases of breast cancers (1-3). To study the biological function of the tumor suppressor BRCA1, we have proposed to perform genetic screening using a lentiviral vector based cDNA library which expresses 17,500 full length human and mouse genes. The library features a number of novelties over traditional ones, including broader target cell range, high efficiency, high quality, easier recovery of target genes and full length cDNAs. This methodology will not only uncover genes involved in BRCA1 tumor suppressor function but also lead to a general application to functional studies in cancer biology. The possible target genes isolated from the screens will contribute to the improvement of the understanding the biology of inherited breast cancer as well as the diagnosis and treatment of breast, ovarian and possibly other cancers. The identified genes will provide targets for the pharmaceutical industry to develop chemopreventive agents, a novel concept to our knowledge that will allow proactive intervention with the diagnosis of a BRCA1 mutation.

BODY

We have proposed to perform genetic screening using a lentiviral vector cDNA library to undertake the following three tasks:

- 1. Cloning, identification, and characterization of genes that bypass BRCA1 deficiency mediated developmental arrest**
- 2. Identification and cloning of gene(s) cooperating with BRCA1 to confer resistance to DNA damage**
- 3. In vivo validation of BRCA1 second site suppressors.**

In the past year, we have made a significant progress in task 2 which will be described in detail below. As for task 1, we failed to isolate sufficient amount of BRCA1^{-/-} MEFs due to the poor proliferation property of the cells. Thus, as proposed in the statement of work, we will have to perform the screen using mouse fibroblast derived from animals that have the endogenous BRCA1 floxed. We have successfully isolated such fibroblasts containing floxed allele spanning exon 5 to 13 (NCI Mouse Repository). We are constructing a modified self-deleting CRE lentiviral vector which contains a puromycin cassette downstream of the LoxP site in the U3 of the remnants of the LTR. Thus after expression of CRE and deletion of the endogenous floxed BRCA1 allele and the CRE expressing vector, it will still leave a puromycin expressing cassette integrated in the genome.

BRCA1 deficient HCC1937 cells are unusually sensitive to DNA damage induced by gamma irradiation. We exploited this sensitivity to screen for dominant suppressors of this phenotype by introduction of a lentiviral library containing 17,500 full length human cDNAs as described in the main body of the grant. In our experience in the irradiation of this cell line we typically irradiate 10,000 to 50,000 cells with a dose of 4.5 Gray. At this dose the cells typically do not survive or form not more than 2 or 3 colonies as an upper limit. BRCA1 reconstituted cells typically form around 20 to 40 colonies under these identical conditions. This indicates that even a full reversal of the BRCA1 defect only leads to approximately to the survival of one out

of a 1000 reconstituted cells. When using a library only single or a few cells are expected to be transduced with any given cDNA, thus irradiation under the same conditions would most likely miss a gene that might rescue or ameliorate the phenotype. Thus we designed a screen based on many rounds of enrichment of lower sublethal doses of radiation that should give selective growth advantage to those genes that had a positive effect on proliferation in the presence of DNA damage (Fig. 1).

To accomplish this we irradiated HCC1937 cells with incremental doses ranging from 1.0 Gray to 3.0 Gray allowing 48 hours for recovery. In the present study we performed seven rounds of such irradiations. After the final round of irradiation we pooled all the surviving cells and extracted DNA from the pooled population. By PCR amplification using T3 and T7 primers, which flank the cDNA insert, we identified 6 distinct bands ranging in size from approximately 0.7 kbp to 2.8 kbp. (Figure2). Control HCC1937 cells that were not infected with the library yielded no products.




Figure 1. Scheme of the lentiviral library screening.




Figure 2. The PCR products of the pooled surviving cells. PCR products had to be reamplified for sequencing purposes. Sequencing of these clones identified the following genes (Table1).

Table 1. Summary of clones identified after gamma irradiation selection

Clone	Identity	Accession #	Description
5-1	Unknown protein	BC009103	Novel ORF overlapping COX4
5-2	Tumor suppressor	AF156165	Putative tumor suppressor in -5q syndrome
5-4	L36A-like protein	NM_001001	Similar to human Ribosomal protein L36
5-5	PKCBP1	BC060508	Protein Kinase C binding protein 1
5-6	H3.3B	BC067757	Histone variant H3.3 B

To validate the candidates, we have transfected clones 5-1, 5-4, 5-5, and 5-6 into an expression lentiviral vector, pBOB-CAG. We will individually transduce them into HCC1937 cells and subject the cells to irradiation and observe the resistance of these cells. Once the clones are validated, we will further characterize the mechanism of these clones in substituting BRCA1 in conferring resistance to DNA damage. Obviously, all clones are novel factors that have not been reported in DNA damage repair pathways. We did not identify BRCA1 as a positive clone can be explained by the absence of this gene in the cDNA library.

KEY RESEARCH ACCOMPLISHMENTS

1. Established mouse fibroblasts harboring floxed BRCA1 allele spanning exons 5 to 13.
2. Identified and cloned four novel factors cooperating with BRCA1 to confer resistance to DNA damage.

REPORTABLE OUTCOME

1. Established mouse fibroblasts harboring floxed BRCA1 allele spanning exons 5 to 13.

CONCLUSION

Based on our initial screening, we have identified a number of candidates that are involved in DNA damage repair pathway mediated by BRCA1, which is an important aspect of tumor suppression of the molecular. As none of the candidates have previously been reported to play a role in DNA damage repair pathway we speculate that some novel components, such as RNA or chromatin structure, might be involved. Once verified and fully investigated, the possible target genes will contribute to the understanding of the biology of inherited breast cancer as well as the diagnosis and treatment of breast, ovarian and possibly other cancers.

REFERENCES

1. Hall, J.M., et al., Linkage of early-onset familial breast cancer to chromosome 17q21. *Science*, 1990. 250(4988): p. 1684.
2. Narod, S.A., et al., Familial breast-ovarian cancer locus on chromosome 17q12-q23. *Lancet*, 1991. 338: p. 82.
3. Smith, S.A., et al., Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. *Nat. Genet.*, 1992. 2: p. 128.